Recently, semi-annual reports of domestic and foreign pharmaceutical companies have been disclosed one after another. From the data released by major companies, we put aside the highly anticipated revenue data and focus on the R&D investment of pharmaceutical companies. Leaving aside the huge gap of R&D investment amount between Chinese head pharmaceutical companies and the international leading pharmaceutical companies in the past, according to the annual report data of listed domestic pharmaceutical companies, the recent few years have seen a continuous increase of R&D expenses of domestic pharmaceutical companies, but most of the expenses are invested in the field of biopharmaceuticals and a few head chemical pharmaceuticals.
Recently, semi-annual reports of domestic and foreign pharmaceutical companies have been disclosed one after another. From the data released by major companies, we put aside the highly anticipated revenue data and focus on the R&D investment of pharmaceutical companies. Among multinational pharmaceutical companies, we can see that Roche ranks first in R&D expenditure with an investment of USD 7.75 billion (the R&D expenses account for 23.86%). According to Roche's annual report data in recent years and the list of R&D investment of global pharmaceutical companies published in recent years, we can see that in recent years, Roche's expenditure on R&D has been ranked first in the world: in 2017, it was 11.8 billion US dollars, ranking first in the world; in 2018, it was 10.8 billion US dollars, ranking first in the world; in 2019, it was as high as 12.31 billion US dollars, accounting for 19.0% of its total revenue. In 2020, R&D investment of Roche was 13 billion Swiss francs (about 13.85 billion US dollars), ranking first in the world and accounting for 22.2% of R&D investment. From the above data, it can be seen that Roche, as a representative company of multinational pharmaceutical companies, invests a lot in R&D, and its R&D expenditure ranks first for many years. The core idea of this business strategy is to attach importance to R&D, pursue the development of new products, and increase strength for the sustainable development of enterprises and strong control over the market.
The pharmaceutical industry is a knowledge-intensive industry, and R&D innovation is the core theme of pharmaceutical companies and the fundamental guarantee for sustainable vitality. R&D investment is not only an important factor to measure the strength and potential of R&D innovation, but also one of the main influencing factors of pharmaceutical R&D output, while the level of R&D fundamentally determines the international competitiveness of the whole industry. In recent years, the global R&D expenditure of the pharmaceutical industry has maintained steady growth, and the global drug R&D is increasingly popular. According to incomplete statistics, the global drug R&D expenditure reached USD182 billion in 2019. New molecular drugs are constantly appearing in the fields of the treatment of cancer, diabetes, cognitive impairment, rare diseases, inflammation and others. Biomedicine has entered a high-speed development stage. Diagnostic techniques and therapies are closely combined and complement each other. Monoclonal antibody, immunotherapy, cell therapy, gene therapy, stem cell therapy and other technologies and drugs are constantly emerging and gradually maturing. New progress has been made in the fundamental frontier disciplines of medicine. Especially in the severe situation of COVID-19 from 2020 to 2021, the fact that the advent of test kits, preventive drugs (vaccines) and therapeutic drugs has further proven the significance of strengthening the construction of fundamental frontier disciplines.
Looking back at the R&D investment of domestic medical surgical supply companies, people in the industry feel pressure. Leaving aside the huge gap of R&D investment amount between Chinese head pharmaceutical companies and the international leading pharmaceutical companies in the past, according to the annual report data of listed domestic pharmaceutical companies, the recent few years have seen a continuous increase of R&D expenses of domestic pharmaceutical companies, but most of the expenses are inv...
(All Rights Reserved)